VIDEO: BRAF-MEK combination represents ‘important new therapy’ for melanoma

Source: Healio, June 2018

Victor Sandor, MD, chief medical officer of Array Biopharma, spoke with HemOnc Today about the FDA’s approval of a two-drug combination for a subset of patients with melanoma.

The agency today approved use of the BRAF inhibitor encorafenib (LGX818, Array BioPharma) and the MEK inhibitor binimetinib (MEK162, Array BioPharma) for treatment of BRAF-mutant advanced, unresectable or metastatic melanoma.

read the original full article